Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat

被引:11
|
作者
Bang, Damodar [2 ]
Shah, Tapan [1 ]
Thakker, Divyesh [3 ]
Shah, Yogesh [2 ]
Raval, Amit D. [1 ]
机构
[1] Nirma Univ, Deparment Pharmacol, Inst Pharm, Ahmadabad, Gujarat, India
[2] Smt NHL Municipal Med Coll, Dept Dermatol Venereol & Leprol, Ahmadabad, Gujarat, India
[3] Shrimati Kaumudiniben Hlth Outcome Res Grp, Patient Safety Unit, Dhrangadhra, Gujarat, India
关键词
Stevens-Johnson syndrome; ibuprofen; antibiotics; India; analgesics; antiepileptics; TOXIC EPIDERMAL NECROLYSIS; ERYTHEMA MULTIFORME; CLINICAL CLASSIFICATION; INVOLVEMENT; ETIOLOGY; RISK;
D O I
10.1002/pds.3212
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose The aims of the present article were to study clinical features and to analyse them in different drug class associated with StevensJohnson syndrome (SJS) in a tertiary care hospital in Gujarat, India. Materials and Methods A prospective hospital-based study was carried out over a period of 3 years (June 2007 to September 2009) at Sheth Vadilal Hospital, Ahmedabad, India. The diagnosis of SJS was made mainly on the basis of the clinical findings, which included extensive erythema multiforme, purpuric lesions with bullae and detachment of skin involving at least two mucous membranes. Further, in each patient suspected with SJS, various laboratory tests such as complete blood count, liver function tests, metabolic panel, chest X-ray and other serological test were carried out. SJS was confirmed on the basis of most widely accepted Bastuji-Garin definition. Causality assessment was performed using the Naranjo scale. Only ` probable' and ` definite' reactions were included. Results Antibacterials for systemic use, anti-inflammatory and antirheumatic products and antiepileptics were the drug classesmost commonly associated (8 of 29 cases, each) with SJS. Individually, ibuprofen was involved in the highest number of cases (five cases, 17.2%), followed by carbamazepine (four cases, 13.8%). The mean duration of developing SJS symptoms was 15.9 days (SD = 8.7 days) and improvement after treatment was 14.2 days (SD = 4.6 days). The duration of appearing SJS symptoms varied significantly between different classes of drugs (p< 0.001). The appearance of SJS symptom started within 10 days for anti-inflammatory and antibacterial compared with 24 days of antiepileptic agents. All the patients with antiepileptic agent-induced SJS had 7% to 9% of detached body surface area. In two patients, SJS progressed to toxic epidermal necrolysis and of which one led to death and the other developed long-termcomplication of conjunctival xerosis. A total of six patients developed long-term complications: four patients had conjunctival synechia, one patient had conjunctival xerosis and one patient had urethral stricture. Conclusion More than 80% of the SJS events were induced by antibacterial, anti-inflammatory and antiepileptic agents with same frequency. The duration of the appearance of SJS symptoms significantly varied between different drug classes and started within 10 days for anti-inflammatory and antibacterial compared with 24 days of antiepileptic agents. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:384 / 395
页数:12
相关论文
共 50 条
  • [41] A SYSTEMATIC REVIEW OF TREATMENT OF DRUG-INDUCED STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS IN CHILDREN
    Del Pozzo-Magana, Blanca R.
    Lazo-Langner, Alejandro
    Carleton, Bruce
    Castro-Pastrana, Lucila I.
    Rieder, Michael J.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2011, 18 (01): : E121 - E133
  • [42] Spontaneous ADR Reports of Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Taiwan
    Su, Chun-Hul
    Hsieh, Yow-Wen
    Gau, Churn-Shiouh
    Yen, H. C.
    DRUG SAFETY, 2009, 32 (10) : 917 - 918
  • [43] Stevens-Johnson Syndrome Induced by Masitinib
    Chaigne, Benjamin
    Lagier, Louise
    Aubourg, Alexander
    de Muret, Anne
    Jonville-Bera, Annie-Pierre
    Machet, Laurent
    Samimi, Mahtab
    ACTA DERMATO-VENEREOLOGICA, 2012, 92 (02) : 210 - 212
  • [44] Stevens-Johnson syndrome induced by levetiracetam
    Zou, Li-Ping
    Ding, Chang-Hong
    Song, Zhen-Jiang
    Li, Xiao-Feng
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2012, 21 (10): : 823 - 825
  • [45] A CASE OF STEVENS-JOHNSON SYNDROME WITH THROMBOCYTOPENIA
    Chester, H.
    Jariwala, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S19 - S19
  • [46] Stevens-Johnson syndrome: a case report
    Yazicioglu, M.
    Iscan, B.
    Turgut, B.
    Yalcin, O.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2009, 37 (04) : 219 - 221
  • [47] Stevens-Johnson Syndrome Induced by Vandetanib
    Yoon, Jimi
    Oh, Chee Won
    Kim, Chi Yeon
    ANNALS OF DERMATOLOGY, 2011, 23 : S343 - S345
  • [48] Stevens-Johnson syndrome induced by acetazolamide
    Her, Young
    Kil, Min S.
    Park, Ju H.
    Kim, Chul W.
    Kim, Sang S.
    JOURNAL OF DERMATOLOGY, 2011, 38 (03): : 272 - 275
  • [49] STEVENS-JOHNSON SYNDROME INDUCED BY CLOFIBRATE
    WONG, SS
    ACTA DERMATO-VENEREOLOGICA, 1994, 74 (06) : 475 - 475
  • [50] Stevens-Johnson syndrome induced by doxylcycline
    Cac, Natalie N.
    Messingham, Michael J.
    Sniezek, Patrick J.
    Walling, Hobart W.
    CUTIS, 2007, 79 (02): : 119 - 122